scholarly journals Availability of Circulating MicroRNAs as a Biomarker for Early Diagnosis of Diffuse Large B-Cell Lymphoma

2015 ◽  
Vol 05 (04) ◽  
pp. 48-58 ◽  
Author(s):  
Katsushige Inada ◽  
Yasushi Okoshi ◽  
Yukiko Cho ◽  
Hitoaki Saito ◽  
Tatsuo Iijima ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Circulating Micrornas ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Meningeal recurrence of intravascular large B-cell lymphoma: early diagnosis with PET-CT

2007 ◽  
Vol 137 (5) ◽  
pp. 386-386 ◽  
Author(s):  
Michael S. Hofman ◽  
Paul Fields ◽  
Lynny Yung ◽  
N. George Mikhaeel ◽  
Robin Ireland ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Pet Ct ◽  
Large B Cell

scholarly journals Early Diagnosis of Intravascular Large B-Cell Lymphoma: Clues From Routine Blood Smear Morphologic Findings

2014 ◽  
Vol 45 (3) ◽  
pp. 248-252 ◽  
Author(s):  
Sagar S. Patel ◽  
Garth A. Aasen ◽  
Michelle M. Dolan ◽  
Michael A. Linden ◽  
Robert W. McKenna ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
B Cell ◽  
Blood Smear ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Routine Blood ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Early diagnosis of intravascular large B-cell lymphoma

2016 ◽  
Vol 14 (11) ◽  
pp. 1146-1148 ◽  
Author(s):  
Sylvia Hurlbeck ◽  
Beate Weidenthaler-Barth ◽  
Florian Butsch
Keyword(s):  
Early Diagnosis ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Renal intravascular large B-cell lymphoma with early diagnosis by renal biopsy: A case report and review of the literature

2009 ◽  
Vol 33 (5) ◽  
pp. 728-730 ◽  
Author(s):  
Nozomi Niitsu ◽  
Daisuke Okamura ◽  
Naoki Takahashi ◽  
Ken Tanae ◽  
Yuki Hagiwara ◽  
...  
Keyword(s):  
Case Report ◽  
Early Diagnosis ◽  
B Cell ◽  
Renal Biopsy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Review Of The Literature ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study

2018 ◽  
Vol 10 ◽  
pp. 1179299X1878109 ◽  
Author(s):  
Céline Bouvy ◽  
Adeline Wannez ◽  
Fabienne George ◽  
Carlos Graux ◽  
Christian Chatelain ◽  
...  
Keyword(s):  
Complete Remission ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Residual Tumor ◽  
Tumor Evolution ◽  
Circulating Micrornas ◽  
Large B Cell Lymphoma ◽  
Prospective Longitudinal ◽  
Large B Cell

Objectives: Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous in terms of phenotype and treatment response in patients. These characteristics make the prognosis difficult to establish and hinder the use of new personalized treatments in clinical practice. In this context, there is currently a need to define new biomarkers enabling a better definition of DLBCL subtypes, prognosis evaluation, and an overview of the resistance to chemotherapeutics. The aim of this study was to evaluate the use of microRNAs found in plasma from patients with DLBCL as biomarkers of tumor evolution in these patients. Method: For this purpose, a plasma biobank was created with samples from patients with DLBCL. The evolution of the level of selected microRNAs during treatment has been studied. A total of 19 patients with DLBCL were included in this pilot mono-centered study and a total of 68 samples were analyzed. Results: The first step of this study was the selection of the microRNAs to be quantified in all the samples of the biobank and that could potentially be used as biomarkers. To this end, quantification of 377 microRNAs was performed on the plasma samples of 2 selected patients with DLBCL and 1 healthy donor with no history of cancer. Among the 377 microRNAs evaluated, 7 were selected and analyzed in the entire biobank. Conclusions: This study highlighted 5 circulating microRNAs whose plasma levels would be worth further investigating for the characterization of DLBCL evolution in patients. MiR-21 and miR-197 had a significant higher plasmatic level in patients with tumors unresponsive to treatment. With a higher plasma level in patients with complete remission, miR-19b, miR-20a, and miR-451 could enable to differentiate, at the remission review, patients with residual tumor, from patients with complete remission.

Sign in / Sign up

Export Citation Format

Share Document